Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Next Previous
Trial Profile

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Trilaciclib (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Registrational
  • Sponsors G1 Therapeutics

    • Most Recent Events

    • 07 Jun 2022 Results of pooled analysis from the G1T28-05 and G1T28-02 trials presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2022 Results of post-hoc analysis data pooled from G1T28-05 and G1T28-02 trials published in the Simcere Pharmaceutical Group Media Release.
    • 02 Jun 2022 Results from a post-hoc analysis of (NCT02499770 , NCT03041311 , NCT02514447 ) were presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top